Can New Pain Drugs Break Through To A Growing Cancer Market and Beyond?
Executive Summary
Two new drug approvals represent the latest innovations in the emerging area of breakthrough cancer pain, designed to ease intense, short-term waves of heightened suffering in patients who are already taking opioids for persistent background pain.
You may also be interested in...
Shared REMS For Transmucosal Fentanyls Could Expand Market For Meda’s Onsolis As It Exits More Restrictive Program
Class-wide Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products will begin operations in March 2012, with participants in REMS for individual products to be transitioned automatically to the new system.
Shared REMS For Transmucosal Fentanyls Could Expand Market For Meda’s Onsolis As It Exits More Restrictive Program
Class-wide Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products will begin operations in March 2012, with participants in REMS for individual products to be transitioned automatically to the new system.
Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls
FDA's decision to create a class Risk Evaluation and Mitigation Strategy for all transmucosal fentanyl products indicates that the agency could take a similar strategy with the extended-release opioids.